Aurinia to focus on marketing of sole drug after failing to find buyer
15 Feb 2024
ImmunotherapyDrug ApprovalAcquisition
Aurinia Pharmaceuticals will halt further development of its experimental immune modulating drugs in order to focus on commercialisation of the lupus treatment Lupkynis (voclosporin). The streamlining follows a strategic review started in June last year, which included reaching out to over 60 parties, but failed to lead to a formal takeover offer.
The board “determined that the ongoing commercial transformation provides the best means for enhancing near-term value for shareholders and other stakeholders,” remarked chairman Daniel Billen. Lupkynis became the first oral therapy approved for adults with active lupus nephritis in the US when the FDA cleared it in 2021, with EU regulators following suit a year later.
The company’s pipeline contains two other preclinical assets, which will both now be scrapped. These comprise AUR200, an immune modulator of BAFF and APRIL activity, and AUR300, which modulates M2 macrophages via the macrophage mannose receptor CD206. Aurinia indicated that due to the overhaul, it will reduce staff numbers by at least 25% in the first quarter, although commercial roles will not be affected.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.